ScholarIQanswers from OpenAlex
Novo Nordisk (Denmark)
InstitutionResearch output, impact & collaborations
Novo Nordisk (Denmark) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Novo Nordisk (Denmark)?
ScholarIQrecord summary
Novo Nordisk (Denmark) is a research organisation in Copenhagen, DK. OpenAlex records 13,546 works and 1,516,992 citations for it. 3,664 researchers list it as their most recent affiliation.
How many works does Novo Nordisk (Denmark) have?
ScholarIQindexed works
Novo Nordisk (Denmark) has 13,546 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Novo Nordisk (Denmark) have?
ScholarIQcitation count
Novo Nordisk (Denmark) has 1,516,992 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Novo Nordisk (Denmark)?
ScholarIQresearcher count
Novo Nordisk (Denmark) has 3,664 researchers in the ScholarIQ index.
What is the average h-index at Novo Nordisk (Denmark)?
ScholarIQavg h-index
Novo Nordisk (Denmark) has an average h-index of 35.4 in OpenAlex.
What is the ROR of Novo Nordisk (Denmark)?
ScholarIQror
The ROR for Novo Nordisk (Denmark) is on the source record.
What is the OpenAlex record for Novo Nordisk (Denmark)?
ScholarIQopenalex
The OpenAlex for Novo Nordisk (Denmark) is on the source record.
Who are the most-cited researchers behind Novo Nordisk (Denmark)?
ScholarIQtop researchers by citations
What are the most-cited papers on Novo Nordisk (Denmark)?
ScholarIQmost cited works
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Juan Esteban Gómez‐Mesa, Stefan Janssens, James L. Januzzi, José Ramón González‐Juanatey, Béla Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr Ponikowski, Michele Senni, David Sim, Jindřich Špinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragoş Vinereanu, Jian Zhang, Peter E. Carson, Carolyn S.P. Lam, Nikolaus Marx, Cordula Zeller, Naveed Sattar, Waheed Jamal, Sven Schnaidt, Janet Schnee, Martina Brueckmann, Stuart Pocock, Faı̈ez Zannad, Milton Packer
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt‐Lindberg, G. Kees Hovingh, Steven E. Kahn, Robert F. Kushner, Ildiko Lingvay, Tuğçe Kalaycı Oral, Marie Mide Michelsen, Jorge Plutzky, Christoffer W. Tornøe, Donna H. Ryan
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
Børge G. Nordestgaard, M. John Chapman, Steve E. Humphries, Henry N. Ginsberg, L. Masana, Olivier Descamps, Olov Wiklund, Robert A. Hegele, Frederick J. Raal, Joep C. Defesche, Albert Wiegman, Rodrigo da Silva Santos, Gerald F. Watts, KG Parhofer, G. Kees Hovingh, Petri T. Kovanen, Cathérine Boileau, Maurizio Averna, Jan Borén, E. Bruckert, Alberico L. Catapano, Jan Albert Kuivenhoven, P. Pajukanta, Kausik K. Ray, A.F.H. Stalenhoef, Erik S.G. Stroes, Marja‐Riitta Taskinen, Anne Tybjærg‐Hansen, for the European Atherosclerosis Society Consensus Panel
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain
Cardiovascular Disease in Chronic Kidney Disease
Joachim Jankowski, Jürgen Floege, Danilo Fliser, Michael Böhm, Nikolaus Marx
How much of the research on Novo Nordisk (Denmark) is open access?
ScholarIQopen access share
92%OPEN ACCESS